We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Breast Cancer Cells Characterized by Microspectroscopy

By LabMedica International staff writers
Posted on 05 Nov 2012
A diagnostic tool has been developed that identifies the metastatic ability of breast cancer cells based on the characterization of the lipid component of the cells. More...


The characterization of the lipids associated with malignancy has been possible due to technological development of a spectroscopic device named Raman (RS) and forms the basis for introducing this technique in routine cytological diagnosis.

Scientists at the Bellvitge Biomedical Research Institute (IDIBELL; Barcelona, Spain) assessed the different profiling of the lipid composition of breast cancer cells, which permitted differentiation of the lipogenic phenotype according to the proportion of unsaturated fatty acids. The investigators cultured breast cancer cells and applied immunochemistry, before submitting the samples to Raman microspectroscopy

The Renishaw Raman system (Apply Innovation; Wotton-under-Edge, UK) comprises of a 514 nm laser that supplies an excitation beam of about 10 mW power, which is focused onto the sample via a microscope. The cytoplasm lipids were measured by RS in a position near the nucleus and outside the endoplasmic reticulum area, where the Nile red staining showed major lipid concentration. The lipid phenotype associated to breast cancer malignancy belongs to Raman spectra acquired in the range of 2,820-3,030 cm−1.

The authors concluded that Raman spectroscopy is a promising technique in biomedical studies due to its noninvasive character and high specificity. The cytology techniques used have found a correlation between the activation of lipogenesis, the chemical reaction leading to fatty acids in an organism, and the amount of saturated fats in metastatic cells indicating a worse prognosis and a decreased survival. The lipid content of the breast cancer cells might be a useful measure to determine various functions coupled to the progression of breast cancer. Àngels Sierra, PhD, the senior author, said, “The algorithm for the discrimination of the metastatic ability is a first step towards the stratification of breast cancer cells using this quick and reactive tool." The study was published on October 17, 2012, in the journal Public Library of Science ONE.

Related Links:

Bellvitge Biomedical Research Institute
Apply Innovation



New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Molecular Test
BD Onclarity HPV Assay
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.